Skip to main content
SpringerLink
Log in

Non-Hypervascular Hypointense Nodules at Gadoxetic Acid MRI: Hepatocellular Carcinoma Risk Assessment with Emphasis on the Role of Diffusion-Weighted Imaging

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Introduction and Aim

In cirrhotic patients, the characterization of hypovascular nodules, hypointense on hepatobiliary phase gadoxetic acid disodium-enhanced magnetic resonance images (Gd-EOB-DTPA-enhanced MRI), is essential to look for the proper approach strategy. Our objective was to evaluate the imaging features and risk assessment of hypovascular nodules, hypointense on Gd-EOB-DTPA-enhanced MRI, focusing on the diagnostic value of diffusion-weighted imaging (DWI).

Material and Methods

This prospective study includes 35 patients with 50 hypovascular hypointense nodules. Signal intensity on T2-weighted images and DWI, vascular pattern on dynamic contrast-enhanced MRI and on hepatobiliary phase, and volume doubling time were analyzed for each nodule as well as patient’s clinical features. Univariate and multivariate analyses were made to determine the variables associated with the development of hypervascular pattern.

Results

On 24 months follow-up period, 40% of the hypointense nodules (mean size 14 mm ± 6.1) became hypervascular hepatocellular carcinoma (HCC) with 6 and 12 months cumulative risk of 45 and 55%. Nine/12 (75%, mean size 15.50 mm ± 7.2) that appeared hyperintense in DWI at first exam show malignant transformation (p value = 0.007). Univariate and multivariate analyses identified hyperintensity at initial DWI (OR 6.49; 95% CI 1.28–32.80; p value = 0.009) and size ≥10 mm (OR 6.22; 95% CI 1.57–24.63; p value = 0.024) as independent factors with the development of HCC.

Conclusion

In conclusion, hypovascular lesions ≥10 mm and those hyperintense in DWI were associated with progression to hypervascular HCC. A close follow-up or histological characterization is recommended to improve patients outcome and to develop effective treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Globocan (2008), Cancer data sheet. Cited 11th December 2012. http://globocan.iarc.fr/factsheets/cancers/liver.asp.

  2. Al Hasani F, Knoepfli M, Gemperli A, Kollar A, Banza V, Kettenbach J, et al. Factors affecting screening for hepatocellular carcinoma. Ann Hepatol. 2014;13:204–10.

    PubMed  Google Scholar 

  3. Gaba RC, Kallwitz ER, Parvinian A, Bui JT, Von Roenn NM, Berkes JL, et al. Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients. Ann Hepatol. 2013;12:766–73.

    PubMed  Google Scholar 

  4. Bruix J, Sherman M, American Association for the Study of Liver Disease. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2. doi:10.1002/hep.24199.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Memeo R, De Blasi V, Cherkaoui Z, Dehlawi A, De’Angelis N, Piardi T, et al. New approaches in locoregional therapies for hepatocellular carcinoma. J Gastrointest Cancer. 2016;47(3):239–46. doi:10.1007/s12029-016-9840-6.

    Article  PubMed  CAS  Google Scholar 

  6. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular Neoplasia. Hepatology. 2009;49:658–64. doi:10.1002/hep.22709.

    Article  Google Scholar 

  7. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology. 2010;254:47–66. doi:10.1148/radiol.09090021.

    Article  PubMed  Google Scholar 

  8. Culverwell AD, Sheridan MB, Guthrie JA, Scarsbrook AF. Diffusion-weighted MRI of the liver—interpretative pearls and pitfalls. Clin Radiol. 2013;68:406–14. doi:10.1016/j.crad.2012.08.008.

    Article  PubMed  CAS  Google Scholar 

  9. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, et al. Management of hepatocellular carcinoma: report of consensus meeting in the 45th Annual Meeting of the Japan Society of Hepatology. Hepatol Res. 2010;40:667–85. doi:10.1111/j.1872-034X.2010.00673.

    Article  PubMed  Google Scholar 

  10. Schwartz M. A biomathematical approach to clinical tumor growth. Cancer. 1961;14:1272–94.

    Article  PubMed  CAS  Google Scholar 

  11. Van Beers BE, Pastor CM, Hussain HK. Primovisteovist: what to expect? J Hepatol. 2012;57:421–9. doi:10.1016/j.jhep.2012.01.031.

    Article  PubMed  Google Scholar 

  12. Park YN. Update on precursor and early lesions of hepatocellular carcinomas. Arch Pathol Lab Med. 2011;135:704–15. doi:10.1043/2010-0524-RA.1.

    Article  PubMed  Google Scholar 

  13. Silva AC, Evans JM, McCullough AE, Jatoi MA, Vargas HE, Hara AK. MR imaging of hypervascular liver masses: a review of current techniques. Radiographics. 2009;29:385–402. doi:10.1148/rg.292085123.

    Article  PubMed  Google Scholar 

  14. Di Pietropaolo M, Briani C, Pilozzi E, Carbonetti F, David V, Iannicelli E. Gd-EOB-DTPA-enhanced magnetic resonance findings of a giant inflammatory hepatocellular adenoma: a case report and review of the literature. J Gastrointest Cancer. 2015;46:421–5. doi:10.1007/s12029-015-9715-2.

    Article  PubMed  Google Scholar 

  15. Imura S, Shimada M, Utsunomiys T. Recent advances in estimating hepatic functional reserve in patients with chronic liver damage. Hepatol Res. 2015;45:10–9. doi:10.1111/hepr.12325.

    Article  PubMed  CAS  Google Scholar 

  16. Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, et al. Expression of AOTP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol. 2009;44:793–8. doi:10.1007/s00535-009-0056-4.

    Article  PubMed  CAS  Google Scholar 

  17. Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, Koda W, et al. The uptake transporter OATP8 expression decreases during multistepshepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol. 2011;21:2056–66. doi:10.1007/s00330-011-2165-8.

    Article  PubMed  Google Scholar 

  18. Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol. 2010;20:2405–13. doi:10.1007/s00330-010-1812-9.

    Article  PubMed  Google Scholar 

  19. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology. 1995;22:983–93.

    Article  Google Scholar 

  20. Huh J, Kim KW, Kim J, Yu E. Pathology-MRI correlation of hepatocarcinogenesis: recent update. J Patho Transl Med. 2015;49:218–29. doi:10.4132/jptm.2015.04.15.

    Article  Google Scholar 

  21. Lee DH, Lee JM, Lee JY, Kim SH, Kim JH, Yoon JH, et al. Non hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enahnced MRI: risk of HCC recurrence after radiofrequency ablation. J Hepatol. 2015;62:1122–30. doi:10.1016/j.jhep.2014.12.015.

    Article  PubMed  CAS  Google Scholar 

  22. Kurokohchi K, Deguchi A, Masaki T, Himoto T, Yoneyama H, Kobayashi M, et al. Successful treatment of hypovascular advanced hepatocellular carcinoma with lipiodol-targeting intervention radiology. Word J Gastroenterol. 2007;13:4398–400.

    Article  Google Scholar 

  23. Kim SH, Lim HK, Kim MJ, Choi D, Rhim H, Park CK. Radiofrequency ablation of high-grade dysplastic nodules in chronic liver disease: comparison with well-differentiated hepatocellular carcinoma based on long-term results. Eur Radiol. 2008;18:814–21.

    Article  PubMed  Google Scholar 

  24. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology. 1998;28:1241–6.

    Article  PubMed  CAS  Google Scholar 

  25. Bartolozzi C, Battaglia V, Bargellini I, Bozzi E, Campani D, Pollina LE, et al. Contrast-enhanced magnetic resonance imaging in 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdom Imaging. 2013;38:290–6. doi:10.1007/s00261-012-9952-9.

    Article  PubMed  Google Scholar 

  26. Iannicelli E, Di Pietropaolo M, Marignani M, Briani C, Federici GF, DelleFave G, et al. Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase. Radiol Med. 2014;119:367–76. doi:10.1007/s11547-013-0364-x.

    Article  PubMed  Google Scholar 

  27. Jang KM, Kim SH, Kim YK, Choi D. Imaging features of subcentimeterhypointense nodules in gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease. Acta Radiol. 2015;56:526–35. doi:10.1177/0284185114534652.

    Article  PubMed  Google Scholar 

  28. Inoue T, Hyodo T, Murakami T, Takayama Y, Nishie A, Higaki A, et al. Hypovascular hepatic nodules showing hypointense on the hepatobiliary-phase image of Gd-EOB-DTPA-enhanced MRI to develop a hypervascular hepatocellular carcinoma: a nationwide retrospective study on their natural course and risk factors. Dig Dis. 2013;31:472–9. doi:10.1159/000355248.

    Article  PubMed  Google Scholar 

  29. Kim YK, Lee WJ, Park MJ, Kim SH, Rhim H, Choi D. Hypovascular hypointense nodules in hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to Hypervascular HCC. Radiology. 2012;265:104–14.

    Article  PubMed  Google Scholar 

  30. Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, et al. Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology. 2013;266:480–90. doi:10.1148/radiol.12112677.

    Article  PubMed  Google Scholar 

  31. Komatsu N, Motosugi U, Maekawa S, Shindo K, Sakamoto M, Sato M, et al. Hepatocellular carcinoma risk assessment using gadoxetic acid-enhnaced hepatocyte phase magnetic resonance imaging. Hepatol Res. 2014;44:1339–46. doi:10.1111/hepr.12309.

    Article  PubMed  CAS  Google Scholar 

  32. Park MJ, Kim YK, Lee MW, Lee WJ, Kim YS, Kim SH, et al. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology. 2012;264:761–70. doi:10.1148/radiol.12112517.

    Article  PubMed  Google Scholar 

  33. Piana G, Trinquart L, Meskine N, Barrau V, Beers BV, Vilgrain V. New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol. 2011;55:126–32. doi:10.1016/j.jhep.2010.10.023.

    Article  PubMed  Google Scholar 

  34. Park MJ, Kim YK, Lee MH, Lee JH. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis. Acta Radiol. 2013;54:127–36. doi:10.1258/ar.2012.120262.

    Article  PubMed  Google Scholar 

  35. Girometti R, Furlan A, Esposito G, Bazzocchi M, Como G, Soldano F, et al. Relevance of b-values in evaluating liver fibrosis: a study in healthy and cirrhotic subjects using two single-shot spin-echo echo-planar diffusion-weighted sequences. J Magn Reson Imaging. 2008;28:411–9. doi:10.1002/jmri.21461.

    Article  PubMed  Google Scholar 

  36. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology. 2003;226:71–8.

    Article  PubMed  Google Scholar 

  37. Lee MH, Kim SH, Park MJ, Park CK, Rhim H. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. AJR Am J Roentgenol. 2011;97:868–75. doi:10.2214/AJR.10.6237.

    Article  Google Scholar 

  38. Kudo M, Matsui O, Izumi N, Lijima H, Kadoya M, Imai Y, et al. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014;3:458–68. doi:10.1159/000343875.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Matsuda M, Ichikawa T, Amemiya H, Maki A, Watanabe M, Kawaida H, et al. Preoperative gadoxetic acid-enhanced MRI and simultaneous treatment of early hepatocellular carcinoma prolonged recurrence-free survival of progressed hepatocellular carcinoma patients after hepatic resection. HPB Surg. 2014;641685 doi:10.1155/2014/641685.

  40. Nathan H, Hyder O, Mayo SC, Hirose K, Wolfgang CL, Chiti MA, et al. Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis. Ann Surg. 2013;258:1022–7. doi:10.1097/SLA.0b013e31827da749.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiology Unit, Sapienza University of Rome, Sant’Andrea Hospital, Rome, Italy

    Chiara Briani, Marco Di Pietropaolo, Francesco Carbonetti, Vincenzo David & Elsa Iannicelli

  2. Department of Digestive and Liver Disease, Sapienza University of Rome, Sant’Andrea Hospital, Rome, Italy

    Massimo Marignani & Paola Begini

Authors
  1. Chiara Briani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Di Pietropaolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Massimo Marignani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Carbonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paola Begini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vincenzo David
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Elsa Iannicelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chiara Briani.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Briani, C., Di Pietropaolo, M., Marignani, M. et al. Non-Hypervascular Hypointense Nodules at Gadoxetic Acid MRI: Hepatocellular Carcinoma Risk Assessment with Emphasis on the Role of Diffusion-Weighted Imaging. J Gastrointest Canc 49, 302–310 (2018). https://doi.org/10.1007/s12029-017-9952-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-017-9952-7

Keywords

Search

Navigation